Clovis' Rubraca leads to 44% ORR in Phase II for CRPC

Clovis Oncology Inc. (NASDAQ:CLVS) said twice-daily oral Rubraca rucaparib led to a confirmed objective response rate (ORR) by investigator assessment of 44% in 25 evaluable patients with a BRCA1/2 mutation in the Phase II TRITON2 trial to treat metastatic castration-resistant prostate cancer. The data were presented at the European Society for Medical Oncology meeting in Munich.

Responses were evaluated using RECIST/Prostate Cancer Working Group (PCWG3) criteria. Median duration of response has not yet been reached. In 45 evaluable prostate-specific antigen (PSA; KLK3) response-evaluable patients with a BRCA1/2 mutation, Rubraca led to a confirmed PSA response rate of 51%...